Cision PR Newswire, Author at World Lifestyler

No Result

View All Result

WORLD LIFESTYLER

No Result

View All Result

Home Author

Cision PR Newswire

Press Releases

Finnate Listed on PathFin.ai Knowledge Hub under the MAS Pathfinder Programme Following Independent Review and Verification Process

June 7, 2026

Press Releases - Lifestyle

Sportradar Group AG (SRAD) Investors: July 17, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP

June 7, 2026

Press Releases

VolitionRx Announces Pricing of $4.6 Million Public Offering

June 7, 2026

Press Releases - Lifestyle

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

June 7, 2026

Press Releases - Lifestyle

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

June 7, 2026

Press Releases - Lifestyle

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

June 7, 2026

Press Releases - Lifestyle

Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

June 7, 2026

Press Releases - Lifestyle

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

June 7, 2026

Press Releases - Lifestyle

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

June 7, 2026

Press Releases - Lifestyle

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

June 7, 2026

Page 656 of 3568 Prev 1 … 655 656 657 … 3,568 Next

No Result

View All Result

Home

Cision PR Newswire

Finnate Listed on PathFin.ai Knowledge Hub under the MAS Pathfinder Programme Following Independent Review and Verification Process

Sportradar Group AG (SRAD) Investors: July 17, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP

VolitionRx Announces Pricing of $4.6 Million Public Offering

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

Recommended

JustMarkets: Top Trading Trends in Southeast Asia – What 2026 Is Showing So Far

Monster Energy’s Alessandro Costa Defeats Stewart Nicoll at UFC Fight Night 272

Popular News

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2026

New Riyadh fertility centre supports Saudi Vision 2030 by bringing internationally recognised reproductive expertise closer to home

Corgi Insurance Welcomes Robert E. Barlow Jr. as EVP of Partnerships to Drive Expansion in Community Association and Property & Casualty Insurance

Chinese Researchers Develop Fast, Precise Method for Platinum-Group Catalyst Synthesis

FROM YOUNGSTAR TO GRAND SLAM CHAMPION: LINDA NOSKOVÁ CONQUERS WIMBLEDON

Connect with us

About & Contact

Explore Content

Legal & Privacy

Tiny Media Brands